Cargando...
Successful rechallenge of cetuximab following severe infusion-related reactions: a case report
Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is associated with a risk of infusion reactions, similar to other infusional agents. Although avoiding a rechallenge with cetuximab following a severe infusion reaction is preferable, this may not be an option if few oth...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
AME Publishing Company
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3937754/ https://ncbi.nlm.nih.gov/pubmed/24653637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2014.02.02 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|